Lipoprotein-Associated Phospholipase A2 (Lp-Pla2) (602)

LpPLA2 is an enzyme produced by monocytes/macrophages that breaks down phospholipids. Increased blood levels of LpPLA2 are associated with soft, active growing plaque.*

*NOTE: Soft plaque is not stable calcified plaque.

Methodology

Enzyme Colormetric

Predicts CVD risk independent of LDL-C and other inflammatory markers.1 Associated with:

• 2-fold increased risk for coronary events
• 2-fold increased risk for stroke

References:

1. Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008;101(Suppl):51F-57F.